Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades

SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
May 17, 2021 08:42 ET | Source: Skye Bioscience, Inc.

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study

THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours,...
April 22, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

Novel glaucoma drug ready for next development phase - GLP toxicology study – on critical path to first human clinical trialOngoing development of THCVHS includes near-term preclinical comparison with...
April 15, 2021 08:45 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at Upcoming Investment Conferences in April

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
March 18, 2021 08:45 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at Benzinga Biotech Small Cap Conference

San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
March 16, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment

San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
March 08, 2021 08:39 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
March 03, 2021 08:37 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
February 03, 2021 09:09 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Investment Conferences in February

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
January 19, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience

San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...